UFC heavyweight James Mulheron will be sitting out a year.
The UK’s James Mulheron, who was pulled from the UFC Shanghai card in November after testing positive for a banned substance, has accepted a one year suspension from USADA. The anti-doping organization announced the news in a press release Tuesday.
Mulheron, (11-2), tested positive for clomiphene and its metabolite, hydroxyclomiphene, the U.S. Anti-Doping agency announced. The result came following an out-of-competition urine test administered on November 10, 2017. Mulheron’s one-year suspension is effective retroactively to November 17, when his provisional suspension was imposed.
Per Tuesday’s release:
Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency Prohibited List.
Clomiphene is not approved by the U.S. Food & Drug Administration (FDA) or the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) for use in the male population, as its use has not been thoroughly studied for safety and efficacy. Clomiphene also indirectly promotes the secretion of testosterone. Increasing testosterone, especially when combined with strength training, has been demonstrated to increase fat-free mass, muscle size, and strength in males, potentially leading to performance enhancement in sport.
The heavyweight lost his UFC debut against Justin Willis at UFC Fight Night 113 last July.
Mulheron’s USADA run-in, of course, was not the only to impact the UFC Shanghai card. UFC middleweight legend Anderson Silva was also pulled from the event after failing an out-of-competition drug test leading up to the event.